Cargando…

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

INTRODUCTION: In lung adenocarcinoma, the mutational spectrum is dominated by EGFR and KRAS mutations. Improved knowledge about genomic and transcriptional alterations in and between mutation-defined subgroups may identify genes involved in disease development or progression. METHODS: Genomic profil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Planck, Maria, Edlund, Karolina, Botling, Johan, Micke, Patrick, Isaksson, Sofi, Staaf, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812039/ https://www.ncbi.nlm.nih.gov/pubmed/24205279 http://dx.doi.org/10.1371/journal.pone.0078614

Ejemplares similares

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
por: Birgisson, Helgi, et al.
Publicado: (2015)

KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
por: Sundström, Magnus, et al.
Publicado: (2010)

Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non‐small cell lung cancer
por: Salomonsson, Annette, et al.
Publicado: (2020)

CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma
por: Isaksson, Sofi, et al.
Publicado: (2017)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics
por: Grundberg, Ida, et al.
Publicado: (2013)

Relation between smoking history and gene expression profiles in lung adenocarcinomas
por: Staaf, Johan, et al.
Publicado: (2012)

Quantification of Normal Cell Fraction and Copy Number Neutral LOH in Clinical Lung Cancer Samples Using SNP Array Data
por: Göransson, Hanna, et al.
Publicado: (2009)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
por: Prencipe, Berardino, et al.
Publicado: (2023)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer
por: Micke, Patrick, et al.
Publicado: (2019)

Identification of sample annotation errors in gene expression datasets
por: Lohr, Miriam, et al.
Publicado: (2015)

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer
por: Mayrhofer, Markus, et al.
Publicado: (2014)

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
por: Eltahir, Mohamed, et al.
Publicado: (2021)

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
por: Smits, Alexander J. J., et al.
Publicado: (2012)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer
por: Jabs, Verena, et al.
Publicado: (2017)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity
por: Rasmussen, Markus, et al.
Publicado: (2011)

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

Performance of gene expression–based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers: a case comparison study in non-small cell lung cancer
por: Cirenajwis, Helena, et al.
Publicado: (2019)

Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer
por: Sandström Gerdtsson, Anna, et al.
Publicado: (2023)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
por: PAPADOPOULOU, EIRINI, et al.
Publicado: (2015)

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
por: Pinheiro, Gil, et al.
Publicado: (2020)

Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma
por: Ringnér, Markus, et al.
Publicado: (2016)

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations
por: Leal, Letícia Ferro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e93ptvrllotitng1ogoc0mlpr3